You can buy or sell MRTX and other stocks, options, ETFs, and crypto commission-free!
Mirati Therapeutics, Inc. Common Stock, also called Mirati Therapeutics, is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Read More Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Seeking AlphaMay 14
Mirati fortunes with KRAS inhibitor tied to Amgen's - JPMorgan
JPMorgan analyst Anupam Rama says Mirati Therapeutics (MRTX +1% ) may experience volatility related to Amgen's (AMGN +0.5% ) fortunes with pipeline candidate AMG 510, in early-stage development for certain types of cancer.
Yahoo FinanceMay 7
What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Mirati Therapeutics, Inc. (NASDAQ:MRTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be deal...
Expected Aug 1, After Hours